Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High Grade Glioma (HGG)

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

Principal Investigator:
Ashley Plant, MD

Research Coordinator:
Dorian Chan
(714) 509-8646

Visit clinicaltrials.gov for more information about this trial.



  • Clinical Trial Info
  • IRB Number: 1711125
  • Sponsor: Novartis Pharmaceuticals Corporation
  • Protocol Number: CDRB436G2201
  • NCT Number: NCT02684058
  • Research Type: Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors
  • Phase: II
  • Status: Active - Closed to Enrollment

Key Inclusion Criteria:

  • Age: 6 Years to 17 Years
  • Diagnosis of BRAF V600 mutant High Grade glioma that has relapsed, progressed or failed to respond to frontline therapy
  • Diagnosis of BRAF V600 mutant Low Grade glioma whose tumor is unresectable and who require treatmentConfirmed measurable disease

Key Exclusion Criteria:

  • ​Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK inhibitorCancer treatment within the past 3 weeks
  • Stem cell transplant within the past 3 months
  • History of heart disease
  • Pregnant or lactating females

Long Live Childhood

Facebook Twitter Pinterest Instagram Snapchat LinkedIn YouTube